Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: A prospective study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 4, 2011, Pages 657-662

  Buchs, Nicolas C ^a   Bühler, Leo ^a   Bucher, Pascal ^a   Willi, Jean Pierre ^a   Frossard, Jean Louis ^a   Roth, Arnaud D ^a   Addeo, Pietro ^a   Rosset, Antoine ^a   Terraz, Sylvain ^a   Becker, Christoph D ^a   Ratib, Osman ^a   Morel, Philippe ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Computed tomography; Contrast enhanced; Detection; Pancreatic cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 79952860341     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06525.x     Document Type: Article

References (34)

1. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br. J. Surg. 2004; 91: 586-94.
2. Ahmad NA, Kochman ML, Lewis JD etal. Endosonography is superior to angiography in the preoperative assessment of vascular involvement among patients with pancreatic carcinoma. J. Clin. Gastroenterol. 2001; 32: 54-8.
3. Arslan A, Buanes T, Geitung JT. Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur. J. Radiol. 2001; 38: 151-9.
4. DeWitt J, Devereaux B, Chriswell M etal. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann. Intern. Med. 2004; 141: 753-63.
5. Soriano A, Castells A, Ayuso C etal. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am. J. Gastroenterol. 2004; 99: 492-501.
6. Bottger TC, Boddin J, Duber C, Heintz A, Kuchle R, Junginger T. Diagnosing and staging of pancreatic carcinoma-what is necessary? Oncology 1998; 55: 122-9.
7. Snady H, Bruckner H, Siegel J, Cooperman A, Neff R, Kiefer L. Endoscopic ultrasonographic criteria of vascular invasion by potentially resectable pancreatic tumors. Gastrointest. Endosc. 1994; 40: 326-33.
8. Yeo CJ, Cameron JL, Sohn TA etal. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann. Surg. 1997; 226: 248-57.
9. 18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J. Gastrointest. Surg. 2005; 9: 22-8.
10. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003; 125: 1235-45.
11. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J. Hepatobiliary Pancreat. Surg. 2004; 11: 4-10.
12. Heinrich S, Goerres GW, Schafer M etal. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 2005; 242: 235-43.
13. 18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89: 2547-54.
14. Hosten N, Lemke AJ, Wiedenmann B, Bohmig M, Rosewicz S. Combined imaging techniques for pancreatic cancer. Lancet 2000; 356: 909-10.
15. 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009; 250: 957-63.
16. 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1775-85.
17. Goh BK, Tan YM, Chung YF. Utility of fusion CT-PET in the diagnosis of small pancreatic carcinoma. World J. Gastroenterol. 2005; 11: 3800-2.
18. 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J. Nucl. Med. 2004; 45: 1279-86.
19. 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 527-31.
20. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin. Radiol. 2007; 62: 745-51.
21. 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J. Nucl. Med. 2008; 49: 1408-13.
22. Farma JM, Santillan AA, Melis M etal. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann. Surg. Oncol. 2008; 15: 2465-71.
23. 18)F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur. J. Radiol. 2009; PMID: 19854016.
24. 18F]fluoroethyl-deoxylactose PET/CT. PLoS One 2009; 4: e7977.
25. Delbeke D, Rose DM, Chapman WC etal. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J. Nucl. Med. 1999; 40: 1784-91.
26. 18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur. J. Nucl. Med. 1997; 24: 678-82.
27. 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am. J. Roentgenol. 2009; 193: 343-8.
28. 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J. Clin. Gastroenterol. 2006; 40: 923-9.
29. 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20: 109-16.
30. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann. Surg. 1999; 229: 729-37.
31. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann. Surg. 2007; 246: 932-7.
32. Ruf J, Lopez Hanninen E, Oettle H etal. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005; 5: 266-72.
33. Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies. Surg. Oncol. Clin. N. Am. 2010; 19: 235-54.
34. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin. Nucl. Med. 2006; 36: 248-56.